



UNIVERSITY OF LEEDS

This is a repository copy of *Effects of Interleukin-1 β Inhibition on Incident Hip and Knee Replacement: Exploratory analyses from a randomized, double-blind, placebo-controlled trial*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/163825/>

Version: Supplemental Material

Article:

Schieker, M, Conaghan, PG orcid.org/0000-0002-3478-5665, Mindeholm, L et al. (7 more authors) (2020) Effects of Interleukin-1 β Inhibition on Incident Hip and Knee Replacement: Exploratory analyses from a randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine*, 173 (7). pp. 509-515. ISSN 0003-4819

<https://doi.org/10.7326/M20-0527>

© 2020 American College of Physicians. All Rights Reserved. This is an author produced version of an article published in *Annals of Internal Medicine*. Reproduced with permission from the publisher.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

SUPPLEMENTARY APPENDIX

Effects of Interleukin-1 β Inhibition on Incident Hip and Knee Replacement:

Exploratory analyses from a randomized, double-blind, placebo-controlled trial

Matthias Schieker, M.D.+, Philip G Conaghan, M.D.+, Linda Mindeholm, M.D.,

Jens Praetgaard, Ph.D., Daniel H. Solomon, M.D., Celeste Scotti, M.D., Herman Gram, Ph.D.,

Tom Thuren, M.D., Ronenn Roubenoff, M.D. and Paul M Ridker, M.D.

TABLE OF CONTENTS

Supplemental Table 1: Terms used by the investigators to describe the nature of the AEs and incidence rates in patients with and without medical history of OA

Supplemental Table 2: Baseline clinical characteristics by medical history of OA and treatment group

Supplemental Figure 1. Cumulative incidence of THR or TKR in participants treated with placebo compared to canakinumab at 50 mg, 150 mg, or 300 mg administered once every three months (A, top); and placebo compared to all participants treated with canakinumab regardless of dose (B, bottom). Data are shown on an intention-to-treat basis for trial participants without a prior history of gout, gouty arthritis, or rheumatoid arthritis.

Supplemental Figure 2: Cumulative incidence of the secondary supportive sensitivity endpoint of worsening OA symptoms or new OA adverse events in participants treated with placebo compared to canakinumab at 50 mg, 150 mg, or 300 mg administered once every three months. Data are shown on an intention-to-treat basis for those with peripheral OA at study entry.

Supplementary Table 1: Terms used by the investigators to describe the nature of the AEs and incidence rates in patients with and without medical history of OA

AE preferred term	AE lower level term	OA in medical history (N = 1569)(%)	No OA in medical history (N = 8492)(%)
Nodal OA	Total	0	2 (0)
	Heberden's nodes	0	2 (0)
OA	Total	236 (15)	267 (3.1)
	Ankle OA	4 (0.3)	6 (0.1)
	Arthrosis	4 (0.3)	12 (0.1)
	Coxarthrosis	19 (1.2)	33 (0.4)
	Degenerative joint disease	4 (0.3)	7 (0.1)
	Elbow OA	3 (0.2)	3 (0)
	Erosive OA	1 (0.1)	0
	Finger OA	0	7 (0.1)
	Foot OA	4 (0.3)	3 (0)
	Generalised OA	0	1 (0)
	Generalized OA	1 (0.1)	4 (0)
	Gonarthrosis	12 (0.8)	39 (0.5)
	Hand OA	6 (0.4)	8 (0.1)
	Hip arthrosis	3 (0.2)	14 (0.2)
	Hips OA	11 (0.7)	12 (0.1)
	Knee OA	12 (0.8)	21 (0.2)
	Localised OA	1 (0.1)	0
	Localized OA	0	1 (0)
	OA hip	2 (0.1)	6 (0.1)
	Omarthrosis	5 (0.3)	9 (0.1)

O.A. shoulders	1 (0.1)	3 (0)
OA	8 (0.5)	25 (0.3)
OA aggravated	139 (8.9)	14 (0.2)
OA deformans	0	1 (0)
OA flare up	1 (0.1)	1 (0)
OA knee	14 (0.9)	30 (0.4)
OA knees	3 (0.2)	8 (0.1)
OA shoulders	2 (0.1)	2 (0)
Osteoarthritis	0	6 (0.1)
Osteoarthritis generalized	0	1 (0)
OA, generalized, involving hand	0	1 (0)
OA, localized, primary, involving forearm	0	1 (0)
Rhizarthritis	0	1 (0)
Shoulder OA	9 (0.6)	15 (0.2)
Thumb OA	3 (0.2)	7 (0.1)
Toe OA	1 (0.1)	0
Wrist OA	4 (0.3)	2 (0)

AE, adverse event; OA, osteoarthritis



Supplemental Table 2: Baseline clinical characteristics by medical history of OA and treatment group

Demographic variable ¹	Medical history of OA		No OA in the medical history	
	Canakinumab Pooled (N=1073)	Placebo (N=496)	Canakinumab Pooled (N=5644)	Placebo (N=2848)
Age – y	64.9 (9.1)	64.3 (8.9)	60.4 (10.7)	60.5 (10.7)
Sex, F – no. (%)	390 (36.3)	165 (33.3)	1332 (23.6)	700 (24.6)
Weight (kg)	93.6 (21.5)	95.9 (21.6)	87.54 (19.6)	87.30 (19.7)
BMI (kg/m ²)	32.7 (6.5)	33.0 (6.7)	30.2 (5.7)	30.2 (5.8)
Waist circumference (cm)	109.2 (16.0)	110.1 (16.4)	104.3 (14.5)	104.1 (14.7)
Smoking, current smoker (%)	244 (22.7)	105 (21.2)	1357 (24.0)	660 (23.2)
Smoking, former smoker (%)	531 (49.5)	256 (51.6)	2603 (46.1)	1363 (47.9)
hsCRP (mg/L) (median, q1-q3)	4.15 (2.80-7.00)	4.10 (2.75-6.75)	4.35 (2.85-7.25)	4.05 (2.75-7.15)

1) Values are mean (SD), unless otherwise noted

BMI, Body Mass Index; hsCRP, high sensitivity C-reactive protein; OA, Osteoarthritis

Supplemental Figure 1. Cumulative incidence of THR or TKR in participants treated with placebo compared to canakinumab at 50 mg, 150 mg, or 300 mg administered once every three months (A, top); and placebo compared to all participants treated with canakinumab regardless of dose (B, bottom). Data are shown on an intention-to-treat basis for trial participants without a prior history of gout, gouty arthritis, or rheumatoid arthritis.



Supplemental Figure 2: Cumulative incidence of the secondary supportive sensitivity endpoint of worsening OA symptoms or new OA adverse events in participants treated with placebo compared to canakinumab at 50 mg, 150 mg, or 300 mg administered once every three months. Data are shown on an intention-to-treat basis for those with peripheral OA at study entry.

